Olvi-Vec
Small Cell Lung Cancer (SCLC)
Phase 2Previously Studied
Key Facts
About Genelux
Genelux is pioneering a novel class of oncolytic virotherapies based on its proprietary, genetically modified vaccinia virus platform. The company's lead asset, Olvi-Vec, is in Phase 2/3 development for platinum-resistant/refractory ovarian cancer, with data suggesting potential for improved survival and immune activation. Genelux's strategy centers on demonstrating the efficacy of its platform as a monotherapy and in combination with other immunotherapies to address significant unmet needs in oncology.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer (SCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Alisertib | Puma Biotechnology | Phase 2 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |